ArticleCancers2020
Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- DNA methylation driven genes shape prognosis and tumor immune landscape in rectal cancer.Discover oncology · 2026Article
- A comparison of differential DNA methylation analysis methods for continuous outcomes: implications for epigenetic studies.Epigenomics · 2026Article
- A Retrospective Study of a Postoperative Inflammation-Based Score for Predicting Disease-Free Survival in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy.Cancer management and research · 2026Article
- Risk factors of pathologic complete response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Frontiers in oncology · 2025Article
- Article
- Wavelets-Based Texture Analysis of Post Neoadjuvant Chemoradiotherapy Magnetic Resonance Imaging as a Tool for Recognition of Pathological Complete Response in Rectal Cancer, a Retrospective Study.Journal of clinical medicine · 2024Article
- DNA methylation profile of inflammatory breast cancer and its impact on prognosis and outcome.Clinical epigenetics · 2024Article
- Performance and Dimensionality of Pretreatment MRI Radiomics in Rectal Carcinoma Chemoradiotherapy Prediction.Journal of clinical medicine · 2024Article
- Review
- The Long Non-Coding RNACancers · 2022Article
- Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression.Cancers · 2022Article
- Role of MRI‑based radiomics in locally advanced rectal cancer (Review).Oncology reports · 2022Review
- Clinical implication and management of rectal cancer with clinically suspicious lateral pelvic lymph node metastasis: A radiation oncologist's perspective.Frontiers in oncology · 2022Review
- Exome and Tissue-Associated Microbiota as Predictive Markers of Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer.Frontiers in oncology · 2022Article
- Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.Therapeutic advances in medical oncology · 2022Review
- Article
- Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients.Biomarker research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 3 countries.
Funding
Abstract
The treatment for locally advanced rectal carcinomas (LARC) is based on neoadjuvant chemoradiotherapy (nCRT) and surgery, which results in pathological complete response (pCR) in up to 30% of patients. Since epigenetic changes may influence response to therapy, we aimed to identify DNA methylation markers predictive of pCR in LARC patients treated with nCRT. We used high-throughput DNA methylation analysis of 32 treatment-naïve LARC biopsies and five normal rectal tissues to explore the predictive value of differentially methylated (DM) CpGs. External validation was carried out with The Cancer Genome Atlas-Rectal Adenocarcinoma (TCGA-READ 99 cases). A classifier based on three-CpGs DM (linked to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.